Hepion Pharmaceuticals Operating Expenses Growth & History (HEPA)
Hepion Pharmaceuticals's operating expenses was $4.2M for fiscal 2025.
View full Hepion Pharmaceuticals company overviewHepion Pharmaceuticals annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $4.2M | −$15.2M | −78.48% |
| 2024 | 2024-12-31 | $19.3M | −$29.1M | −60.07% |
| 2023 | 2023-12-31 | $48.4M | $3.0M | +6.51% |
| 2022 | 2022-12-31 | $45.5M | $15.1M | +49.62% |
| 2021 | 2021-12-31 | $30.4M | $10.3M | +50.91% |
| 2020 | 2020-12-31 | $20.1M | $12.4M | +159.28% |
| 2019 | 2019-12-31 | $7.8M | −$6.8M | −46.76% |
| 2018 | 2018-12-31 | $14.6M | $4.1M | +38.71% |
| 2017 · Dec 31 | 2017-12-31 | $10.5M | — | — |
| 2017 · Jun 30 | 2017-06-30 | $21.0M | $218,387 | +1.05% |
| 2016 | 2016-06-30 | $20.8M | $6.8M | +49.04% |
| 2015 | 2015-06-30 | $14.0M | — | — |
Hepion Pharmaceuticals quarterly operating expenses
| Fiscal quarter | Period ended | Operating expenses | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.2M | −$534,020 | −30.59% |
| Q1 2026 | 2026-03-31 | $798,509 | −$482,086 | −37.65% |
| Q4 2025 | 2025-12-31 | $609,683 | −$592,471 | −49.28% |
| Q3 2025 | 2025-09-30 | $527,902 | −$3.9M | −88.16% |
| Q2 2025 | 2025-06-30 | $1.7M | −$6.8M | −79.47% |
| Q1 2025 | 2025-03-31 | $1.3M | −$3.9M | −75.29% |
| Q4 2024 | 2024-12-31 | $1.2M | −$9.2M | −88.45% |
| Q3 2024 | 2024-09-30 | $4.5M | −$6.2M | −58.20% |
| Q2 2024 | 2024-06-30 | $8.5M | −$5.7M | −39.97% |
| Q1 2024 | 2024-03-31 | $5.2M | −$8.0M | −60.77% |
| Q4 2023 | 2023-12-31 | $10.4M | $635,783 | +6.51% |
| Q3 2023 | 2023-09-30 | $10.7M | $2.2M | +25.98% |
| Q2 2023 | 2023-06-30 | $14.2M | −$5.8M | −29.17% |
| Q1 2023 | 2023-03-31 | $13.2M | $6.0M | +82.13% |
| Q4 2022 | 2022-12-31 | $9.8M | $772,920 | +8.59% |
| Q3 2022 | 2022-09-30 | $8.5M | −$52,030 | −0.61% |
| Q2 2022 | 2022-06-30 | $20.0M | $13.1M | +191.75% |
| Q1 2022 | 2022-03-31 | $7.3M | $1.2M | +20.24% |
| Q4 2021 | 2021-12-31 | $9.0M | $4.0M | +81.72% |
| Q3 2021 | 2021-09-30 | $8.5M | $2.3M | +36.69% |
| Q2 2021 | 2021-06-30 | $6.9M | $2.1M | +43.54% |
| Q1 2021 | 2021-03-31 | $6.0M | $1.8M | +44.05% |
| Q4 2020 | 2020-12-31 | $5.0M | $2.7M | +120.88% |
| Q3 2020 | 2020-09-30 | $6.2M | $4.3M | +226.14% |
| Q2 2020 | 2020-06-30 | $4.8M | $3.1M | +181.64% |
| Q1 2020 | 2020-03-31 | $4.2M | $2.3M | +117.88% |
| Q4 2019 | 2019-12-31 | $2.2M | — | — |
| Q3 2019 | 2019-09-30 | $1.9M | — | — |
| Q2 2019 | 2019-06-30 | $1.7M | −$2.2M | −56.35% |
| Q1 2019 | 2019-03-31 | $1.9M | −$1.9M | −50.24% |
| Q2 2018 | 2018-06-30 | $3.9M | — | — |
| Q1 2018 · Mar 31 | 2018-03-31 | $3.9M | −$1.0M | −21.32% |
| Q3 2017 | 2017-03-31 | $4.9M | — | — |
Hepion Pharmaceuticals operating expenses trends
Over the last five fiscal years, Hepion Pharmaceuticals's operating expenses decreased from $20.1M to $4.2M, a change of −$16.0M. The latest reported quarter, Q2 2026, shows $1.2M.
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Hepion Pharmaceuticals source filings ↗